Hasil Pencarian - M. Lübbert

  • Menampilkan 1 - 8 hasil dari 8
Perbaiki Hasil
  1. 1
    Repeat to gene expression ratios in leukemic blast cells can stratify risk prediction in acute myeloid leukemia

    Repeat to gene expression ratios in leukemic blast cells can stratify risk prediction in acute myeloid leukemia oleh M. Onishi-Seebacher, G. Erikson, Z. Sawitzki, D. Ryan, G. Greve, M. Lübbert, T. Jenuwein

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY

    P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY oleh F. Schulz, J. Kostova, B. Hildebrandt, K. Nachtkamp, C. Strupp, N. Gattermann, M. Lübbert, S. Blum, S. Parmentier, K. Götze, J. Lipke, F. Beier, W.-K. Hofmann, U. Germing

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.

    P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. oleh G. Garcia-Manero, S. Bart, J. K. McCloskey, P. Fenaux, D. Selleslag, G. Reda, D. Valcárcel, V. Santini, J. Mayer, B. Xicoy, H. Yamaguchi, M. Lübbert, Y. Miyazaki, H. Keer, Y. Hao, M. Azab, H. Döhner

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    P328: DYNAMIC EVOLUTION OF TCF3-PBX1 LEUKEMIAS AT THE SINGLE-CELL LEVEL UNDER CHEMOTHERAPY PRESSURE

    P328: DYNAMIC EVOLUTION OF TCF3-PBX1 LEUKEMIAS AT THE SINGLE-CELL LEVEL UNDER CHEMOTHERAPY PRESSURE oleh M. Kusterer, M. Lahnalampi, M. Voutilainen, G. Gentile, S. Pennisi, J. Norona, G. Greve, M. Lübbert, R. Sankowski, M. Prinz, S. Killmer, M. Salvat Lago, B. Bengsch, M. Cleary, V. Zachariadis, M. Enge, O. Lohi, M. Heinäniemi, J. Duque-Afonso

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECITABINE IN AML PATIENTS

    P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECI... oleh K. Geissler, Z. Koristek, T. Bernal del Castillo, J. Novák, G. Rodriguez Macias, S. K. Metzelder, A. Illes, A. Nagy, J. Mayer, M. Arnan, M.-M. Keating, J. Krauter, M. Lunghi, N. Stefano Fracchiolla, U. Platzbecker, V. Santini, Y. Sano, A. Oganesian, H. Keer, M. Lübbert

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)

    PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT... oleh A. DeZern, G. Marconi, D. Deeren, M. Diez Campelo, M. Lübbert, P. Krishnamurthy, Z. Nagy, G. Basak, A. Jonášová, E. Morozova, K. Geissler, Y. Ofran, H. Kelley, A. Volkert, K. Baker, Q. Kang-Fortner, G. Hodgson, C. Madigan, D. A. Roth, M. Kelly, P. Fenaux

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA

    P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA oleh F. G. Ruecker, A. Corbacioglu, F. Theis, M. Christopeit, U. Germing, G. Wulf, M. Abu Samra, L. Teichmann, M. Lübbert, M. W. Kühn, M. Bentz, J. Westermann, L. Bullinger, V. I. Gaidzik, E. Jahn, M. Gröger, S. Kapp-Schwoerer, D. Weber, F. Thol, M. Heuser, A. Ganser, H. Döhner, K. Döhner

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG

    S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP,... oleh M. Lübbert, P. Wijermans, M. Kicinski, S. Chantepie, W. van der Velden, R. Noppeney, L. Griskevicius, A. Neubauer, M. Crysandt, R. Vrhovac, M. Luppi, S. Fuhrmann, E. Audisio, A. Candoni, O. Legrand, R. Foà, G. Gaidano, D. van Lammeren-Venema, E. F. Posthuma, M. Hoogendoorn, A. Giraut, M. Stevens-Kroef, J. H. Jansen, E. Ammatuna, J.-P. Vilque, R. Wäsch, H. Becker, N. Blijlevens, U. Dührsen, F. Baron, S. Suciu, S. Amadori, A. Venditti, G. Huls

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: